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 Synopsis 24 
 25 
Background: A considerable number of Gram-negative bacteraemias occur outside 26 
intensive care units (ICUs). Inadequate antibiotic therapy in ICUs has been associated 27 
with adverse outcomes; however, there are no prospective studies in non-ICU patients. 28 
Methods: A 6-month (8/1/06-1/31/07), prospective cohort study of non-ICU patients 29 
with Gram-negative bacteraemia in a tertiary care hospital was performed. Inadequate 30 
empirical antibiotic therapy was defined as no antibiotic or starting a non-susceptible 31 
antibiotic within 24 hours after the initial positive blood culture. 32 
Results: 250 non-ICU patients had Gram-negative bacteraemia. Mean age=56.4 (±16.1) 33 
years. The predominant bacteria in monomicrobial infections were E. coli (24%), K. 34 
pneumoniae (18%), and P. aeruginosa (8%). Sixty-one (24%) patients had polymicrobial 35 
bacteraemia. Seventy patients (28%) required ICU transfer, and 35 (14%) died. 36 
Seventy-nine (31.6%) received inadequate empirical antibiotic therapy. These patients 37 
were more likely to have a hospital-acquired infection [Odds ratio (OR)=1.99, 95% 38 
confidence interval (CI)=1.11-3.56, p=0.02] and less likely to have E. coli 39 
monomicrobial bacteraemia [OR=0.40 (95% CI 0.19-0.86), p=0.02]. There were no 40 
differences in occurrence of sepsis [72 (91.1%) patients with inadequate vs. 159 (93.0%) 41 
with adequate therapy; p=0.6], ICU transfer [20 (25.3%) vs. 50 (29.2%); p=0.5], post-42 
bacteraemia length of stay (median=6.8 vs. 6.1 days; p=0.09) or death [11 (13.9%) vs. 24 43 
(14.0%); p=1.0]. 44 
 Conclusions: Nearly one-third of non-ICU patients with Gram-negative bacteraemia 45 
received inadequate empirical antibiotic therapy. There was no difference in adverse 46 
outcomes between patients receiving inadequate or adequate therapy in this study. 47 
48 
 Introduction 49 
 50 
Approximately 250,000 episodes of bloodstream infections occur in the United 51 
States annually.
1
 Bloodstream infections have an overall mortality rate of 18%, making 52 
them one of the leading causes of death in the U.S.
2
 Over the last two decades, Gram-53 
negative bacteria have become a less frequent cause of bloodstream infections,
3
 since the 54 
increased use of indwelling vascular devices has resulted in a larger proportion of Gram-55 
positive bacteraemias.
1
 However, there is evidence that Gram-negative bacteraemias are 56 
increasing once again.
4
 Antibiotic resistance among Gram-negative bacteria is also 57 
increasing.
5
 There has been limited development of new antibiotics with Gram-negative 58 
activity,
6,7
 which has made the treatment of Gram-negative bacteraemia more difficult. 59 
Previous studies of bloodstream infections have focused primarily on ICU-60 
acquired infections, because critically ill patients represent a well-defined and highly 61 
vulnerable population.
8,9
 However, bloodstream infections among hospitalized patients 62 
outside the ICU account for at least half of all nosocomial bloodstream infections.
10
 63 
These infections in non-ICU patients have rarely been investigated separately.
11,12
 This is 64 
presumably because they were believed to be associated with less morbidity and 65 
mortality than in ICU patients, and also because the distribution of non-ICU patients in a 66 
hospital requires more workforce to conduct a prospective study. Little data are available 67 
on the demographic characteristics of non-ICU patients with Gram-negative bacteraemia, 68 
and their clinical outcomes. 69 
Several studies have demonstrated that inadequate empirical antibiotic treatment 70 
of bacteraemia is associated with poor outcome.
13–16
 These studies have mainly focused 71 
 on ICU patients or have been carried out in diverse populations.
17
 Inadequate empirical 72 
treatment was reported in 23-30% of cases in previous studies. However, a 53% rate of 73 
inadequate treatment was reported in infections due to antibiotic-resistant organisms.
18
 If 74 
similar rates of inadequate treatment exist in non-ICU patients, empirical antibiotic 75 
prescribing practices would need to be re-examined. 76 
In this study, we describe the epidemiology of Gram-negative bacteraemia in non-77 
ICU patients at a tertiary-care hospital, investigate the frequency of inadequate antibiotic 78 
treatment, elicit predisposing factors for inadequate therapy, and determine its impact on 79 
clinical outcomes. 80 
81 
 Patients and Methods 82 
 83 
Setting 84 
Barnes-Jewish Hospital (BJH), a 1250-bed teaching hospital, is the largest hospital in 85 
Missouri, with a referral base that includes the Saint Louis metropolitan area, eastern 86 
Missouri and western Illinois. 87 
 88 
Study design 89 
We performed a prospective cohort study of patients with Gram-negative bacteraemia 90 
during a 6-month period from August 1
st
, 2006 until January 31
st
, 2007. An automated 91 
query of all non-ICU patients with a blood culture growing ≥1 species of Gram-negative 92 
bacilli was performed using electronic data from a BJC Healthcare clinical data 93 
repository and the results were sent daily to one of the investigators (J.M.). 94 
 95 
Inclusion and exclusion criteria 96 
All adult patients admitted to non-ICU wards who presented with or developed Gram-97 
negative bacteraemia (≥1 positive blood culture) were included. Polymicrobial infections 98 
were also included if at least one Gram-negative organism was present. Subsequent 99 
episodes of bacteraemia in study patients were excluded from the analysis. Patients who 100 
were bacteraemic as an outpatient (in clinics or in the emergency department) and who 101 
were discharged to home before the results of the culture were known were excluded. We 102 
also excluded patients who were initially identified as having a Gram-negative 103 
 bacteraemia, but were determined to have Gram-positive organisms in the final 104 
laboratory identification (n=4). 105 
 106 
Data collection 107 
Paper and electronic medical records of patients who met inclusion criteria were 108 
reviewed for demographics, medical history, home medication, and possible sources of 109 
infection. Information on all positive clinical cultures other than blood cultures was also 110 
collected to determine any potential focus of infection. Charlson comorbidity
19
 and 111 
McCabe severity of illness
20
 scores were computed for each patient. Patients’ vital signs, 112 
laboratory, pharmacy, and radiological data were continuously reviewed during the 113 
admission. Medication information was entered sequentially as start and stop date and 114 
time for each antibiotic. 115 
Key clinical outcomes measured included the development of hypotension, multiple 116 
organ dysfunction syndrome, ARDS, mechanical ventilation, any subsequent transfer to 117 




Adequacy of antibiotic therapy was determined at various time periods: 1) within 24 122 
hours of the time the blood culture was drawn, 2) within 24 hours of notification of 123 
bacterial growth (which coincided with the notification of Gram stain results), 3) within 124 
24 hours of bacterial identification, and 4) within 24, 48, and 72 hours of notification of 125 
antibiotic susceptibility results. Inadequacy of antibiotic treatment was defined as no 126 
 antibiotic or no susceptibility-matching antibiotic administered during each of these time 127 
periods in order to reflect the dynamics of inadequate treatment. Various time periods 128 
have been examined in the literature, including antibiotic treatment during a period of 24 129 
hours from time of blood culture sampling,
18,21,14,13,22
 at the time when antibiotic 130 
susceptibility results are available,
23,15
 or during 48 hours from the time of notification of 131 
susceptibilities.
17
 We analyzed inadequate treatment within 24 hours of blood culture 132 
sampling, since this definition has been used in the largest number of studies. If antibiotic 133 
susceptibility testing was not performed, we decided on a case-by-case basis whether 134 
treatment could be considered adequate, based on the antibiogram for that particular 135 




Sepsis, sepsis-induced hypotension, and multiple organ dysfunction syndrome were 138 
defined using established criteria.
25
 A bacteraemia was classified as community-acquired 139 
if the first positive blood culture occurred ≤48 hours after hospital admission.26 140 
Neutropenia was defined as white blood cell count <1.0 G/L. Medical 141 
immunosuppression was defined as receipt of prednisone equivalent of ≥10mg daily or 142 
any other immunosuppressant (e.g., cyclosporine, methotrexate, etc.) during the 30 days 143 
prior to admission. 144 
 145 
Microbiological methods 146 
Work-up of all blood cultures was performed by the BJH Clinical Microbiology 147 
Laboratory. Blood cultures were incubated in the Bactec 9240 system (Becton-Dickinson 148 
 Diagnostic Systems, Sparks, MD). Standard microbiological methods for identification 149 
and antibiotic susceptibility testing were employed.
27
  150 
In our institution, the microbiology laboratory notifies the clinician when a blood culture 151 
becomes positive. Following notification, the clinician is responsible for reviewing 152 
subsequent bacterial identification and antimicrobial susceptibility results in the hospital 153 
computer system. 154 
 155 
Data analysis and statistical methods 156 
Data entry was performed using Microsoft Access and Excel (Microsoft Corp., Redmond, 157 
WA), and data analysis was performed using SPSS 14 (SPSS Inc., Chicago, IL). 158 
Univariate comparisons among categorical variables were performed using the 
2
 159 
test or Fisher’s exact test as appropriate. Comparisons among continuous independent 160 
variables were performed using Student’s t test or Mann Whitney U test as appropriate. A 161 
two-sided p value of <0.05 was considered significant. Variables found to have a p<0.1 162 
on univariate testing were considered for entry into a forward stepwise multivariate 163 
logistic regression model. The study was approved by the Washington University Human 164 
Research Protection Office (No. 06-0638). Due to the observational design of the study 165 
informed consent was not required. 166 
167 
 Results 168 
 169 
The epidemiology of Gram-negative bacteraemia outside the ICU 170 
Two hundred and ninety-four patients had a Gram-negative bacteraemia during the study 171 
period. Of these, 44 (15.0%) patients were ICU patients, leaving 250 patients for analysis 172 
(Table 1). 173 
There were 160 (64.0%) community-acquired and 90 (36.0%) hospital-acquired 174 
infections. The predominant organisms in monomicrobial bacteraemias were E. coli 175 
(n=59; 24%), K. pneumoniae (45; 18%), and P. aeruginosa (19; 8%). Sixty-one 176 
bacteraemias were polymicrobial (24.4%) (Table 2). There were 12 (4.8%) multi-drug 177 
resistant organisms among the isolates. 178 
Two hundred and thirty-one (92.4%) patients were septic at the time of blood culture, 105 179 
(42.0%) developed hypotension, and 11 (4.4%) multiple organ dysfunction syndrome. 180 
Transfer to ICU was necessary in 70 (28.0%) patients. In-hospital mortality was 14.0% 181 
(n=35). 182 
 183 
The frequency of inadequate antibiotic treatment of Gram-negative bacteraemia 184 
The antibiotics with Gram-negative activity that were most frequently prescribed during 185 
the 24-hour period after the initial positive blood culture was drawn were cefepime (109; 186 
in 43.6% of episodes), ciprofloxacin (57; 22.8%), piperacillin/tazobactam (39; 15.6%), 187 
gentamicin (28; 11.2%), ceftriaxone (22; 8.8%), meropenem (9; 3.6%), and 188 
ampicillin/sulbactam (5; 2.0%). In 57 cases (22.8%) more than one antibiotic was given 189 
in this time period. 190 
 Seventy-nine (31.6%) patients received inadequate empirical antibiotic treatment. In 38 191 
(48.1%) of cases inadequate treatment was due to failure to administer antibiotics with 192 
Gram-negative coverage within 24 hours of the initial positive blood culture, and in 41 193 
(51.9%) cases was due to a Gram-negative bacillus that was resistant to the prescribed 194 
antibiotic. Within 24 hours after notification of antibiotic susceptibilities, 28 of 197 195 
patients (14.2%) were still receiving inadequate antibiotic treatment (Figure 1). 196 
 197 
Factors associated with inadequate empirical antibiotic treatment of Gram-negative 198 
bacteraemia 199 
Among patients receiving inadequate versus adequate empirical treatment within the first 200 
24 hours after the initial blood culture was drawn, there were no significant differences in 201 
mean age [55.3 years (±17.0) vs. 56.9 years (±15.8), p=0.5], male gender [43 (54.4%) vs. 202 
83 (48.5%), p=0.4], body mass index (median 25.3 vs. 27.3, p=0.12), Charlson score 203 
(median 3 vs. 4, p=0.4), McCabe score (median 1 vs. 1, p=0.2) (Table 1), or in type of 204 
service admitting the patient (data not shown). Patients with hospital-acquired 205 
bacteraemia were more often inadequately treated than those with community-acquired 206 
bacteraemia [37 (46.8%) vs. 53 (31.0%) patients, p=0.02].  207 
E. coli was less likely to be the cause of inadequately treated bacteraemia [10 208 
(12.7%) vs. 49 (28.7%), p=0.006]. Apart from resistance to ampicillin (58% of 209 
monomicrobial E. coli bacteraemias), E. coli were most often resistant to 210 
trimethoprim/sulfamethoxazole (21; 35.6%), ciprofloxacin (18; 30.5%), gentamicin (7; 211 
11.9%), and piperacillin/tazobactam (2; 3.4%). Treatment was less often inadequate if the 212 
 bloodstream infection had a urinary tract source, [14 (20.9%) urinary vs. 65 (35.5%) non-213 
urinary source, p=0.03]. 214 
In multivariate analysis, hospital-acquired bacteraemia [OR 1.99 (95% CI 1.11-215 
3.56), p=0.02] was associated with receiving inadequate empirical antibiotic treatment. 216 
Mucositis at time of blood culture [OR 0.23 (95% CI 0.06-0.84), p=0.03], and presence 217 
of E. coli monomicrobial bacteraemia [OR 0.40 (95% CI 0.19-0.86), p=0.02] were more 218 
commonly associated with adequate antibiotic use (Table 1). 219 
 220 
The outcome of inadequately empirically treated Gram-negative bacteraemia 221 
Comparing the outcomes of inadequately versus adequately treated infections, there were 222 
no differences in transfer to the ICU [20 (25.3%) vs. 50 (29.2%), p=0.5], length of 223 
hospital stay after positive blood culture [median 6.8 days (range 1-89) vs. 6.1 days (1-224 
106), p=0.09], or in-hospital mortality [11 (13.9%) vs. 24 (14.0%), p=1.0]. When 225 
adjusting the effect of inadequate treatment for the Charlson comorbidity score, previous 226 
exposure to steroids, and neutropenia (all of which had been found to be associated with 227 
mortality in univariate analysis), inadequate treatment did not remain in the final model 228 
(data not shown). There was no difference in mortality whether cefepime had been used 229 
for empirical treatment or not [17 (15.6%) patients exposed to cefepime vs. 18 (12.8%) 230 
not exposed; p=0.5]. 231 
Definitive treatment (defined as administration of an antibiotic that matched the 232 
bacteria’s susceptibility pattern within 24 hours of notification of susceptibilities) was 233 
more often inadequate if empirical antibiotic treatment had been inadequate compared to 234 
 if it had been adequate [20 (30.8%) with inadequate empirical therapy vs. 8 (6.1%) with 235 
adequate empirical therapy, p<0.001]. 236 
237 
 Discussion 238 
 239 
Non-ICU patients account for approximately half of the bloodstream infections in the 240 
hospital.
2,10
 An even larger proportion of Gram-negative bacteraemias (62-95%) occurs 241 
in non-ICU patients.
28–30
 Nevertheless, bacteraemias have rarely been investigated 242 
outside the intensive care unit,
11,12,31
 which may be due to the heterogeneity of non-ICU 243 
patients. To our knowledge, this is the first prospective study of Gram-negative 244 
bacteraemia in the non-ICU hospitalized population. During the study period, non-ICU 245 
patients accounted for 85% (250 of 294) of all Gram-negative bacteraemias in this 246 
hospital. The demographics, comorbidities, and microbiology of infections in this study 247 
are similar to retrospective studies of Gram-negative bacteraemias in hospitalized 248 
patients.
28,29,32,33
 Urinary tract infections were the predominant source of bacteraemia and 249 
E. coli was the most frequently detected organism. This is in contrast to Gram-negative 250 
bacteraemias in ICU patients, which frequently originate from the respiratory
34
 or 251 
gastrointestinal tract
35
 and are more often caused by P. aeruginosa.
31
 252 
Twenty-eight percent of patients were transferred to the ICU after the bacteraemia 253 
had occurred. The in-hospital mortality was substantial (14%), but less than the 24% 254 
mortality rate in a Danish population-based study,
28
 or in studies of ICU patients with 255 
Gram-negative bacteraemia (49-60%).
34,35
 This is likely due to differences in population 256 
characteristics including different levels of severity of underlying illnesses, but might 257 
also point to differences in the management of sepsis rather than antibiotic treatment. 258 
259 
 One of the major modifiable factors influencing the outcome of bacteraemia is the 260 
adequacy of antibiotic treatment.
36
 This was demonstrated in studies including ICU 261 
patients.
13-17,23
 However, no study has examined the effect of adequate antibiotic 262 
treatment on outcomes in non-ICU patients only. We demonstrated rates of inadequate 263 
empirical treatment during the first 24 hours after the blood culture (31.6%) similar to the 264 
30% - 37% reported from other prospective studies.
15,17
 In approximately half of the 265 
cases, inadequate treatment was due to failure to administer an antibiotic with Gram-266 
negative activity. 267 
Hospital-acquired bacteraemia was a risk factor for receiving inadequate 268 
empirical antibiotic treatment in our cohort. This has been noted previously,
22,21,13-15
 and 269 
suggests that physicians are often unaware of the different microbiological patterns in the 270 
hospital versus the community. Increasing antibiotic resistance and lack of prescriber 271 
knowledge regarding appropriate antibiotics for likely in-hospital pathogens may lead to 272 
the institution of inadequate empirical antibiotic treatment. Decision support tools, based 273 
on local bacterial antimicrobial resistance patterns in association with clinical information 274 
and inclusion of Gram stain results, may improve the choice of empirical therapy.
37,38
 275 
Several other risk factors for inadequate treatment have been found, e.g. previous 276 
antibiotic treatment,
14,13





 and Pseudomonas infections,
22
 which we did not 278 
find. Conversely, E. coli infection was associated with less risk of inadequate treatment, 279 
which has been reported before by others.
22,13
 E. coli is the most frequent cause of Gram-280 
negative bacteraemia and is not as prone to multi-drug resistance as other Gram-negative 281 
bacteria,
33
 which may explain why it is generally better covered by empirical 282 
 antimicrobials. The finding that mucositis was protective against inadequate treatment 283 
might be related to mucositis being more often present in a subset of oncology patients, 284 
and a tendency to start broad-spectrum antibiotics with Gram-negative activity earlier in 285 
this population. 286 
 287 
In our cohort of patients, inadequate empirical treatment was not associated with 288 
deterioration of status (transfer to ICU, length of hospital stay, or increased in-hospital 289 
mortality). This is in contrast to many studies, in which inadequate treatment was 290 
associated with adverse outcomes.
13-17,23
 However, a few studies that included mixed ICU 291 
and non-ICU patient populations have not found this association.
22,21
 One possible 292 
explanation for our finding is that non-ICU patients in general have a lower severity of 293 
illness compared to ICU patients and therefore, the role of the adequate antibiotic 294 
treatment may be less crucial.
36
 A study underlining this assumption showed that 295 
inadequate treatment was more frequently administered in less severely ill patients, with 296 
no discernable impact on outcomes.
22
 Interventions focused on optimizing treatment for 297 
non-ICU patients would likely have the greatest benefit in e.g., neutropenic patients, 298 
transplant patients, and patients at risk for Pseudomonas bacteraemia.  299 
In addition, we did not find that the use of cefepime for empirical treatment was 300 




There are some limitations to our study. First, this is a single, tertiary care hospital 303 
and may reflect process issues unique to this facility. In our hospital the clinician is only 304 
directly notified by the microbiology laboratory when a blood culture turns positive, but 305 
 needs to look up subsequent bacterial identification and antimicrobial susceptibility 306 
results in the hospital computer system. This may cause delays in starting adequate 307 
antibiotic treatment. We also only collected crude mortality, not attributable mortality. 308 
The sample size is large for a single-center prospective study but may still be small to 309 




One of the strengths of this prospective study is the detailed sequential analysis of 312 
the adequacy of antibiotic treatment at different time points. Previous studies of the 313 
adequacy of treatment have analyzed one specific time frame and not taken into account 314 
the dynamic that is inherent in the processing of blood cultures and the notification of 315 
results to the treating physician. We also evaluated empirical and definitive therapy 316 
separately, and controlled for baseline severity of illness.
41
 At our institution, antibiotic 317 
treatment is initiated by clinicians from various specialties and levels of professional 318 
experience and is therefore diverse, which adds to the generalizability of our findings. 319 
 320 
Our study is the first to prospectively describe the epidemiology of Gram-321 
negative bacteraemias in non-ICU patients. The frequency of inadequate empirical 322 
antibiotic treatment is similar to data from ICUs. The administration of inadequate 323 
treatment did not confer worse patient outcomes. Therefore, while adequate antibiotic 324 
therapy is an important factor, our findings suggest that there are other factors that may 325 
be more important in determining the prognosis in the non-ICU population. 326 
327 
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Table 1. Comparison of 250 non-ICU patients receiving inadequate versus adequate empirical antibiotic treatment for Gram-467 
negative bacteraemia 468 









p value Odds Ratio (95% 
CI) 
Age, mean (  standard deviation), 
years 
56.4 (±16.1) 55.3 years (±17.0) 56.9 years (±15.8) 0.5 - 
Male gender 126 (50.4%) 43 (54.4%) 83 (48.5%) 0.4 - 
Race      
- White 153 (61.2%)     
- African-American 94 (37.6%)     
- Other 3 (1.2%)     
LTCF resident 33 (13.2%) 12 (15.2%) 21 (12.3%) 0.5 - 
Admitted within 3 months 146 (58.4%) 46 (58.2%) 100 (58.5%) 1.0 - 
BMI (median, range), kg/m
2
 26.4 (13.3-70.4) 25.3 (17.0-70.4) 27.3 (13.3-66.4) 0.12 - 
Charlson comorbidity score (median, 
range) 
4 (0-16) 3 (0-16) 4 (0-15) 0.4 - 
McCabe severity of illness score 
(median, range) 
1 (1-3) 1 (1-3) 1 (1-3) 0.2 - 
Congestive heart failure 30 (12.0%) 6 (7.6%) 24 (14.0%) 0.15 - 
Chronic pulmonary disease 44 (17.6%) 15 (19.0%) 29 (17.0%) 0.7 - 
Malignancy 112 (44.8%) 31 (39.2%) 81 (47.4%) 0.2 - 
- Leukaemia 27 (10.8%) 5 (6.3%) 22 (12.9%) 0.12 - 
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- Metastatic solid tumor 34 (13.6%) 10 (12.7%) 24 (14.0%) 0.8 - 
- Neutropenia 36 (14.4%) 8 (10.1%) 28 (16.4%) 0.2 - 
- Chemotherapy ≤30 days prior to 
admission 
31 (12.4%)     
Received steroids ≤30 days prior to 
admission 
35 (14.0%)     
Other immunosuppressive therapy 30 (12.0%)     
History of solid organ transplant  10 (4.0%)     
Bone marrow transplant (this 
admission) 
10 (4.0%)     
Diabetes mellitus 87 (34.8%) 22 (27.8%) 65 (38.0%) 0.12 - 
Hyperglycemia (>200 mg/dL)  41 (16.4%) 8 (10.1%) 33 (19.3%) 0.07 - 
Renal insufficiency (Cr >1.5 mg/dL) 68 (27.2%) 25 (31.6%) 43 (25.1%) 0.3 - 
Cerebrovascular disease 28 (11.2%) 7 (8.9%) 21 (12.3%) 0.4 - 
Hemiplegia 15 (6.0%) 8 (10.1%) 7 (4.1%) 0.06 - 
Liver disease 26 (10.4%) 12 (15.2%) 14 (8.2%)  0.09 - 
Mucositis at time of blood culture 21 (8.4%) 3 (3.8%) 18 (10.5%) 0.08 0.23 (0.06-0.84) 
Source of bloodstream infection      
- Urinary tract 67 (26.8%) 14 (17.7%) 53 (31.0%) 0.03 - 
- Intravascular catheter 40 (16.0%) 18 (22.8%) 22 (12.9%) 0.047 - 
- GI tract 41 (16.4%)     
- Respiratory tract 9 (3.6%)     
- Other source 28 (11.2%)     
- No source identified 65 (26.0%)     
Hospital-acquired bacteraemia 90 (36%) 37 (46.8%) 53 (31.0%) 0.02 1.99 (1.11-3.56) 
E. coli, monomicrobial infection 59 (23.6%) 10 (12.7%) 49 (28.7%) 0.006 0.40 (0.19-0.86) 
K. pneumoniae, monomicrobial 
infection 
45 (18.0%) 11 (13.9%) 34 (19.9%) 0.3 - 
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P. aeruginosa, monomicrobial 
infection 
19 (7.6%) 7 (8.9%) 12 (7.0%) 0.6 - 
Polymicrobial infection 61 (24.4%) 24 (30.4%) 37 (21.6%) 0.14 - 
Sepsis 231 (92.4%) 72 (91.1%) 159 (93.0%) 0.6 - 
Sepsis-induced hypotension 105 (42.0%) 32 (40.5%) 73 (42.7%) 0.7 - 
Outcomes      
- Multiple organ dysfunction 
syndrome 
11 (4.4%)     
- Transfer to intensive care unit (ICU) 70 (28.0%) 20 (25.3%) 50 (29.2%) 0.5 - 
- Mechanical ventilation after 
bacteraemia 
29 (11.6%)     
- ARDS 6 (2.4%)     
- In-hospital mortality 35 (14.0%) 11 (13.9%) 24 (14.0%) 1.0 - 
 469 
NOTE. LTCF = Long-term care facility. BMI = Body mass index. GI tract = Gastrointestinal tract. ARDS = Acute respiratory distress 470 
syndrome. Variables considered for entry in a forward stepwise multivariate logistic regression model included Hospital-acquired 471 
infection; Source, urinary tract; Source, intravascular catheter; Hemiplegia; E. coli, monomicrobial infection; Hyperglycemia; 472 
Mucositis; Liver disease. The -2 log likelihood value for the final model was 293.796, and the Hosmer-Lemeshow goodness-of-fit chi 473 
square test was 0.861 (p=0.835). 474 
475 
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Table 2. Bacterial isolates in 250 non-ICU patients with Gram-negative bacteraemia 476 
Microorganism n (%) 
n=274 
  Escherichia coli 77 (28%) 
  Klebsiella pneumoniae 67 (24%) 
  Pseudomonas aeruginosa 30 (11%) 
  Enterobacter cloacae 15 (5%) 
  Proteus mirabilis 13 (5%) 
  Acinetobacter baumannii 13 (5%) 
  Klebsiella oxytoca 8 (3%) 
  Stenotrophomonas maltophilia 6 (2%) 
  Other Gram-negative microorganisms 45 (16%) 
 477 
NOTE. Sixty-one (24.4%) of 250 Gram-negative bacteraemia episodes were polymicrobial infections. The most frequent among the 478 
45 other Gram-negative organisms were Enterobacter aerogenes (4), Achromobacter spp. (3), Acinetobacter spp. (3), Citrobacter 479 
freundii (3), Citrobacter koseri (3), Providencia spp. (3), Pseudomonas spp. (3), and Salmonella spp. (3).480 
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Figure 1. Inadequate antibiotic treatment among non-ICU patients with Gram-negative bacteraemia 481 
 482 
 30 
NOTE. Denominator changes due to patient discharge or death. 483 
